Differential effects of glycoprotein B epitope-specific antibodies on human cytomegalovirus-induced cell–cell fusion

References

1. Boyle K. A., Compton T. 1998; Receptor-binding properties of a soluble form of human cytomegalovirus glycoprotein B. J Virol 72:1826–1833
   [Google Scholar]
2. Britt W. J., Vugler L., Butfiloski E. J., Stephens E. B. 1990; Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64:1079–1085
   [Google Scholar]
3. Compton T., Nowlin D. M., Cooper N. R. 1993; Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparin sulfate. Virology 193:834–841
   [Google Scholar]
4. Dimmock N. J. 1993; Neutralization of animal viruses. Curr Top Microbiol Immunol 183:1–149
   [Google Scholar]
5. Eggers M., Bogner E., Agricola B., Kern H. F., Radsak K. 1992; Inhibition of human cytomegalovirus maturation by brefeldin A. J Gen Virol 73:2679–2692
   [Google Scholar]
6. Gicklhorn D., Eickmann M., Radsak K. 1999; Chloramphenicol acetyltransferase expression as a sensor for fusion activity. Biotechniques 27:902–904 906:908
   [Google Scholar]
7. Gonczol E., deTaisne C., Hirka G., Berencsi K., Lin W. C., Paoletti E., Plotkin S. 1991; High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine 9:631–637
   [Google Scholar]
8. Gorman C. M., Moffat L. F., Howard B. H. 1982; Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2:1044–1051
   [Google Scholar]
9. Kari B., Gehrz R. 1992; A human cytomegalovirus glycoprotein complex designated gC-II is a major heparin-binding component of the envelope. J Virol 66:1761–1764
   [Google Scholar]
10. Kari B., Gehrz R. 1993; Structure, composition and heparin binding properties of a human cytomegalovirus glycoprotein complex designated gC-II. J Gen Virol 74:255–264
    [Google Scholar]
11. Kniess N., Mach M., Fay J., Britt W. J. 1991; Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J Virol 65:138–146
    [Google Scholar]
12. Marshall G. S., Rabalais G. P., Stout G. G., Waldeyer S. L. 1992; Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis 165:381–384
    [Google Scholar]
13. Meyer G. A., Radsak K. D. 2000; Identification of a novel signal sequence that targets transmembrane proteins to the nuclear envelope inner membrane. J Biol Chem 275:3857–3866
    [Google Scholar]
14. Meyer H., Sundqvist V. A., Pereira L., Mach M. 1992; Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J Gen Virol 73:2375–2383
    [Google Scholar]
15. Ohizumi Y., Suzuki H., Matsumoto Y., Masuho Y., Numazaki Y. 1992; Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55. J Gen Virol 73:2705–2707
    [Google Scholar]
16. Ohlin M., Sundqvist V. A., Gilljam G., Ruden U., Gombert F. O., Wahren B., Borrebaeck C. A. 1991; Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus. Clin Exp Immunol 84:508–514
    [Google Scholar]
17. Ohlin M., Sundqvist V. A., Mach M., Wahren B., Borrebaeck C. A. 1993; Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol 67:703–710
    [Google Scholar]
18. Ohlin M., Silvestri M., Sundqvist V. A., Borrebaeck C. A. 1997; Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques. Clin Diagn Lab Immunol 4:107–111
    [Google Scholar]
19. Radsak K., Wiegandt H., Unterdorfer G., Wagner C., Kaiser C. J. 1985; Sodium butyrate selectively inhibits host cell glycoprotein synthesis in human fibroblasts infected with cytomegalovirus. Biosci Rep 5:589–599
    [Google Scholar]
20. Schmolke S., Drescher P., Jahn G., Plachter B. 1995; Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear localization signal functions with other portions of the protein to mediate its efficient nuclear transport. J Virol 69:1071–1078
    [Google Scholar]
21. Silvestri M. E., Sundqvist V. A. 2001; An investigation into the heparin-binding properties of a synthetic peptide deduced from the antigenic domain 2 of human cytomegalovirus glycoprotein B. Scand J Immunol 53:282–289
    [Google Scholar]
22. Silvestri M., Sundqvist V. A., Ruden U., Wahren B. 1991; Characterization of a major antigenic region on gp55 of human cytomegalovirus. J Gen Virol 72:3017–3023
    [Google Scholar]
23. Wagner B., Kropff B., Kalbacher H., Britt W., Sundqvist V. A., Ostberg L., Mach M. 1992; A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus. J Virol 66:5290–5297
    [Google Scholar]
24. Whitbeck J. C., Muggeridge M. I., Rux A. H., Hou W., Krummenacher C., Lou H., van Geelen A., Eisenberg R. J., Cohen G. H. 1999; The major neutralizing antigenic site on herpes simplex virus glycoprotein D overlaps a receptor-binding domain. J Virol 73:9879–9890
    [Google Scholar]